Investigational drug · Phase 3
Enpatoran
Also called: M5049, M5049 dose, Enpatoran dose
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
4 still active
All registered trials
9
Any phase or sponsor naming "Enpatoran"
First trial start
2022
Mar 31, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Enpatoran", any sponsor or status.
Conditions studied
As listed on its trial records.
- Systemic Lupus Erythematosus (SLE)
- Cutaneous Lupus Erythematosus (CLE)
- Systemic Lupus Erythematosus
- Systematic Lupus Erythematosus
- Cutaneous Lupus Erythematosus
Approved drugs for the same conditions: Lupus (SLE) · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "Enpatoran" as an intervention, largest first.
- The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)Pivotal-lookingCompleted
EMD Serono Research & Development Institute, Inc.Industry
NCT05162586 · 456 participants · Start Mar 31, 2022 · Primary completion Nov 20, 2024
Drug: Enpatoran low dose; Enpatoran medium dose and 2 more · For: Systemic Lupus Erythematosus
Sites: Torrance, California; Brandon, Florida; Miami, Florida · 153 sites in all
- A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]Pivotal-lookingRecruiting
EMD Serono Research & Development Institute, Inc.Industry
NCT07840287 · 404 participants (planned) · Start Oct 22, 2026 · Primary completion Sep 1, 2031
Drug: Enpatoran · For: Systemic Lupus Erythematosus (SLE); Cutaneous Lupus Erythematosus (CLE)
Sites: Troy, Michigan
- The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)Pivotal-lookingActive, not recruiting
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyIndustry
NCT05540327 · 381 participants · Start Sep 16, 2022 · Primary completion Aug 12, 2028
Drug: M5049 low dose; M5049 medium dose and 2 more · For: Systemic Lupus Erythematosus
Sites: Torrance, California; Brandon, Florida; Miami, Florida · 122 sites in all
- A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)Pivotal-lookingRecruiting
EMD Serono Research & Development Institute, Inc.Industry
NCT07355218 · 202 participants (planned) · Start Apr 1, 2026 · Primary completion May 25, 2029
Drug: Enpatoran; Placebo and 1 more · For: Systematic Lupus Erythematosus; Cutaneous Lupus Erythematosus
Sites: Upland, California; DeBary, Florida; Fort Lauderdale, Florida · 70 sites in all
- A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseasePivotal-lookingRecruiting
EMD Serono Research & Development Institute, Inc.Industry
NCT07332481 · 202 participants (planned) · Start Mar 10, 2026 · Primary completion May 24, 2029
Drug: Enpatoran; Placebo and 1 more · For: Systemic Lupus Erythematosus (SLE); Cutaneous Lupus Erythematosus (CLE)
Sites: Los Angeles, California; Thousand Oaks, California; Cooper City, Florida · 74 sites in all
- A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy ParticipantsCompleted
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyIndustry
NCT06589726 · 40 participants · Start Sep 10, 2024 · Primary completion Dec 2, 2024
Drug: Placebo; Moxifloxacin and 2 more · For: Healthy
Sites: Neu-Ulm, Germany
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyIndustry
NCT06589713 · 34 participants · Start Sep 24, 2024 · Primary completion Apr 13, 2026
Drug: Enpatoran · For: Renal Impairment
Sites: Kiel, Germany
EMD Serono Research & Development Institute, Inc.Industry
NCT05650567 · 20 participants · Start Jan 19, 2023 · Primary completion Jun 25, 2025
Drug: M5049 dose; Placebo · For: Dermatomyositis; Polymyositis
Sites: Phoenix, Arizona; Scottsdale, Arizona; Aurora, Colorado · 31 sites in all
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyIndustry
NCT05110027 · 7 participants · Start Nov 5, 2021 · Primary completion Dec 24, 2021
Drug: Enpatoran; [14C]enpatoran microtracer and 1 more · For: Healthy
Sites: Groningen, Netherlands
Newest research
PubMed records naming it or its code names, newest first.
- TLR7-mediated autoimmunity targets Robo3 to drive astrogliosis in frontotemporal dementia.
Lu R, Choi JJ, Jahan N, et al. · Res Sq 2026
- Modern Therapies for Discoid Lupus Erythematosus: A Narrative Review.
Jonnalagadda A, Richmond RL, Pathak GN, et al. · Dermatol Ther (Heidelb) 2026
- Microglial TLR7 contributes to traumatic brain injury-induced neuroinflammation in mice.
Du YT, Ma XL, Gao SH, et al. · Acta Pharmacol Sin 2026
- TLR7 Inhibition Limits Ischemic Cardiac Injury by Disrupting ITGAM-Dependent Immune-Endothelial Interactions.
Li Y, Yang Y, Park C, et al. · JACC Basic Transl Sci 2026
- Enpatoran: promising mechanism, pharmacodynamic challenge.
Arriens C · Lancet Rheumatol 2026
- Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial.
Morand EF, Werth VP, Wenzel J, et al. · Lancet Rheumatol 2026
Also in development for Systemic Lupus Erythematosus (SLE)
- hUC-MSCsmesenchymal stem cells, MSCPhase 38 trials
Shenzhen Wingor Biotechnology Co., Ltd. · Knee Osteoarthritis, Crohn&Amp;#39;s, Crohn&Amp;#39;s Disease (CD)
- LitifilimabBIIB059Phase 35 trials
Biogen · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus, Lupus Erythematosus, Systemic
- SCTC21CPhase 34 trials
Sinocelltech Ltd. · IgA Nephropathy, Multiple Myeloma (MM), Systemic Lupus Erythematosus (SLE)
- SG301Phase 33 trials
Hangzhou Sumgen Biotech Co., Ltd. · Systemic Lupus Erythematosus (SLE), Relapsed/Refractory Multiple Myeloma, Antibody Mediated Rejection
- Descartes-08Phase 24 trials
Cartesian Therapeutics · Myasthenia Gravis, Generalized, Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV)
- ESG206ESG206-2Phase 23 trials
Shanghai Escugen Biotechnology Co., Ltd · Systemic Lupus Erythematosus (SLE), Immune Thrombocytopenia (ITP), Primary Sjögren Syndrome
- BCMA-CD19-IL-15Phase 22 trials
iCell Gene Therapeutics · Inflammatory Bowel Diseases (IBD), Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
- C-CAR168Phase 22 trials
AbelZeta Inc. · Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Autoimmune Diseases
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.